immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Quantum Immunologics, Inc., a biotechnology company, engages in the research, development, and production of immunologic treatment systems for breast cancer. Its products include individualized cancer immunotherapy system, a system in which blood drawn from a patient is treated with a process and cells are injected back into the patient; cancer monitoring test that uses cancer immunotherapy to monitor blood levels of the immune response in a patient following treatment; and cancer screening test, a blood test. The company is based in Tampa, Florida.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.

Corning SAS manufactures pressed and blown glass for liquid crystal displays. It includes optical communications, environmental technologies, gorilla glass, and life sciences. The company and is headquartered in Samois-sur-Seine, France.

Part of Aptevo Therapeutics, Inc., Aptevo Research & Development LLC is a company headquartered in Olympia, WA. The firm engages in research and development of pharmaceutical and biotechnology.

Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for immunotherapy of cancer. Alligator discovers and develops drug development candidates up to phase IIa clinical studies. Alligator’s pipeline currently counts three immune-modulating projects, ADC-1013, ADC-1015, and ADC-1016. Alligator uses its proprietary technology platforms: ALLIGATOR-GOLD, a unique fully human antibody library, and FIND® (Fragment INduced Diversity), a powerful in vitro based antibody optimization technology, in growing our pipeline.

Helix BioPharma Corp. is an immuno-oncology company, which engages in the development of products for the treatment and prevention of cancer. The company was founded on July 31, 1995 and is headquartered in Toronto, Canada.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.

MSD Italia Srl, part of Merck & Co., Inc., is an Italian company located in Rome. The firm manufactures pharmaceutical products. It was founded in 1891. Nicoletta Luppi is the current CEO, occupying that position since 2003.

National Research Council of Canada, provides research & development. It services include research programs and collaboration opportunities, technical and advisory services, licensing opportunities and industrial research assistance program. The company was founded by Graham W. Burton and is headquartered in Ottawa, ON.

Cancer Research Ventures Ltd. engages in the business of research and experimental development on biotechnology. It provides medical products. The company is headquartered in London, the United Kingdom.

Asana BioSciences LLC is an American private company located in Bridgewater, NJ. The firm operates as a clinical-stage biopharmaceutical company. It was founded in 2014 by Sandeep Gupta and Chintu Patel.\nThe company says this about itself: Asana BioSciences is a clinical stage biopharmaceutical company based in Lawrenceville, NJ. Asana is focused on discovery and development of novel targeted investigational medicines in immunology/inflammation and oncology.

Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.

Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration

Fujirebio Diagnostics AB develops and manufactures immunological reagents. It focuses on the development of monoclonal antibodies which fight against biochemical markers of diseases. The firm distributes products to the international biotech and diagnostic industries. The company is headquartered in Gothenburg, Sweden.

Hubei Quejing Biomedical Co., Ltd., established on 2014-12-09, Business scope includes early detection of malignant tumors,prevention,treat;Biomedical research and development and technology promotion.(Involved in licensing projects,It should be operated after obtaining the permission of the relevant department)

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.